fbpx

PSA22: PSA Symbion Excellence Award Winners Announced

29 July 2022

 

The Pharmaceutical Society of Australia (PSA) is proud to announce the winners of the 2022 PSA Excellence Awards, who were recognised today during the PSA22 conference in Sydney. This year’s Excellence Awards are proudly sponsored by Symbion.

 

The PSA Excellence Awards acknowledge the achievers of the profession: those involved in innovative practice, those who are striving to raise practice standards, and those who, through their professionalism, provide a model of practice which others strive to emulate.

 

The winners of the 2022 PSA Symbion Excellence Awards are:

     Pharmacist of the Year – Faye McMillan, Coolamon, New South Wales.
Early Career Pharmacist of the Year
– Deborah Hawthorne, Wangaratta, Victoria.
     Lifetime Achievement Award – Terence White and Rhonda White, Brisbane, Queensland.

 

PSA National President Dr Fei Sim celebrated the winners and their outstanding contributions to pharmacy and their communities.

 

“I congratulate the award winners for their dedication to the pharmacist profession and their commitment to community health and wellbeing,” she said.

 

“Each of this year’s winners has a unique background, from passion for rural health, to a lifetime of service to accessible community health care.

 

“I am incredibly proud to announce Associate Professor Faye McMillan as the 2022 PSA Pharmacist of the Year for her remarkable career as a pharmacist, and in particular her work within Aboriginal and Torres Strait Islander communities.

 

“Faye has had a great impact on the health of Indigenous Australians, as well as the pharmacy profession more broadly. I cannot think of a pharmacist more deserving of this award.

 

“The 2022 Early Career Pharmacist of the Year Deborah Hawthorne has done fantastic work as a General Practice Pharmacist, ensuring that pharmacist expertise is available where medicines are.

 

“Deborah is demonstrating the innovation, energy, and best practice we love seeing from our early career pharmacists, and we are excited to continue to support her throughout the rest of her promising career.

 

“This year’s Lifetime Achievement Award goes to Queensland powerhouses Terry White AO and Rhonda White AO. Their contributions to pharmacy are too great to list, with thousands of Australian pharmacists knowing them as mentors, confidants, friends and advocates of our profession.

 

“We are pleased to award Terry and Rhonda a joint Lifetime Achievement Award, recognising their lifetime together as advocates for Queensland pharmacy and leaders to pharmacists around Australia.”

 

Symbion CEO Brett Barons also congratulated the award winners.

 

“In this, the eighteenth year Symbion has sponsored the PSA Excellence Awards, we remain as proud as ever with our association,” he said.

 

“The PSA Excellence Awards are the pre-eminent individual awards in our industry and this year’s winners are inspirational. Their contribution to our industry and the lives of so many has been enormous.

 

“I would like to acknowledge Deborah Hawthorne as Early Career Pharmacist, Faye MacMillan as Pharmacist of the Year and Terry and Rhonda White, the trail blazing team we have admired so closely, as worthy recipients of the Lifetime Achievement Award.”

 

PSA extends thanks to award sponsor, Symbion, for their ongoing support of the event, and looks forward to working with them again in 2023.

 

For media notes on the award winners, please contact Georgia Clarke on 0410 505 315 or email georgia.clarke@psa.org.au

PSA launches disability care report at PSA22

29 July 2022

 

Today the Pharmaceutical Society of Australia (PSA) has launched the fifth report in the Medicine Safety Series, Medicine Safety: Disability Care at their flagship national conference, PSA22.

 

The report outlines significant challenges to safe medicine use within the disability sector, including inappropriate prescribing, problems taking medicines, inadequate access to medication management review services, and difficulty accessing health professionals.

 

PSA’s first medicine safety report, Medicine Safety: Take Care estimated that medicine-related problems cause 250,000 hospital admissions each year, with an annual cost of approximately $1.4 billion, and at least half of these hospital admissions being preventable.

 

This latest report highlights the significant difference in life expectancy in Australia, with people with intellectual disability experiencing a 20-32 year shorter lifespan.

 

PSA National President Dr Fei Sim, who launched the report at PSA22, said that more needs to be done to ensure medicine safety for Australians living with disability.

 

“Approximately 4.4 million Australians live with disability, many requiring complex medical care,” she said.

 

“PSA’s Medicine Safety: Disability Care report highlights the many barriers to safe medicine use, ranging from prescribing and dispensing, to administration, and medication management.

 

“The result is a health system that is failing Australians with disability.

 

“This report is an important step in identifying the real and significant issues patients with disability face. It is our duty, as healthcare professionals, to keep working to make care accessible and appropriate for everyone.

 

“A greater focus on medicine safety is key to addressing the health and life expectancy gap for people with disability.

 

“Pharmacists are the key, and we look forward to working with state, territory and federal governments, the disability sector, patients, and their families to improve the provision of care to Australians with disability,” Dr Sim concluded.

 

PSA’s Medicine Safety: Disability Care report is available here.

 

Pharmacists delivering record COVID-19 vaccinations

13 July 2022

 

Australian pharmacists are delivering following surging demand for COVID-19 vaccinations, with figures released by the Department of Health today show that pharmacists have delivered more than 52,000 COVID-19 vaccinations in the last day and over 7.7 million since the start of the rollout.

 

Pharmaceutical Society of Australia (PSA) National President Dr Fei Sim says these vaccination numbers highlight the accessibility of community pharmacists, as well as the trust the public has in Australian pharmacists.

 

“I thank our community pharmacists who have stepped up and been on the front line of the COVID-19 vaccination effort for the last twelve months,” she said.

 

“These vaccination figures show just how critical community pharmacists are in providing timely, accessible healthcare. Nearly 50 per cent of yesterday’s COVID-19 vaccinations were delivered by a pharmacist, in a community pharmacy.

 

“This is on top of administering record numbers of influenza vaccinations, increase in oral antivirals and supporting their own staff being furloughed with COVID or influenza.

 

“Pharmacists around Australia have stepped up when it mattered most, and now that state and territory governments all but closed their vaccination hubs – it is on primary care, led by pharmacists and GPs to do the heavy lifting.

 

“It’s clear that Australians trust the expertise of pharmacists, now it’s time that pharmacists are adequately remunerated for the critical role they play.”

 

Dr Sim also said that growing reliance on community pharmacists indicated a shift in how Australians access primary care, with many heading to their local pharmacy more regularly.

 

“Pharmacists are seeing more patients coming through the doors with minor ailments, and in particular respiratory symptoms. Our pharmacists are doing a fantastic job at supporting patients, including referral to a GP or hospital where appropriate.

 

“PSA is committed to ensuring that pharmacists are remunerated fairly for their time and expertise, so that they can provide the best care to our communities.”

 

 

Media contact: Georgia Clarke 0487 922 176

End of free RAT program puts vulnerable people at risk

12 July 2022

 

The Pharmaceutical Society of Australia (PSA) National President Dr Fei Sim is critical of the Federal Government’s announcement that the COVID-19 Rapid Test Concessional Access Program would not be extended beyond July 2022.

 

Dr Sim says that this move not only puts vulnerable Australians at risk, but also sends the wrong message to the public.

 

“PSA is very concerned about the Federal Government’s plan to cease concessional access to Rapid Antigen Tests (RAT) at the end of the month. It sends the wrong message to the public,” she said.

 

“The pandemic is not over, and the threat of serious illness is still there for many vulnerable people in our communities. Testing remains a vital part of our COVID-19 response.

 

“While recognising that our approach to test-trace-isolate has changed since the program was launched in January, testing with even mild symptoms remains an expectation of everyone in the community.

 

“With most states and territories adopting advice from the Australian Health Protection Principal Committee (AHPPC) to move from a 3-month to a 28-day immunity period, access to testing will be vital, especially for vulnerable groups who’ve relied on the concessional program.

 

“Let’s not forget that case numbers and hospitalisations are still rising every single day. Governments should be encouraging more testing, not less.

 

Dr Sim also pointed out a positive RAT or PCR test was necessary for people to access antiviral medicines.

 

“A patient needs a positive COVID-19 test in order to access antiviral medicines, and for many concession card holders RATs are the only way testing is accessible.

 

“We cannot simply remove the main method of testing that’s accessible to these vulnerable groups. The result will be a lot of people not testing at all.

 

“PSA fully supports an extension of the concessional RAT program to make sure that our most vulnerable have continued access to testing when it’s needed.

 

“We also call on the Federal Government to restore funding to the COVID-19 Home Medicines Service, allowing COVID-positive patients to safely access the medicines they need from home.”

 

PSA strongly supports other important messages to help Australians stay safe, including staying up to date with COVID-19 vaccination, staying home when sick and wearing face masks in indoor public environments

 

 

Media contact: Georgia Clarke 0487 922 176

 

UTI Pharmacy Pilot requires health sector co-operation, not turf wars

8 July 2022

 

Today Pharmaceutical Society of Australia (PSA) Queensland President Shane MacDonald has welcomed the Queensland Government’s announcement that the Urinary Tract Infection Pharmacy Pilot – Queensland (UTIPP-Q) has been extended permanently.

 

Mr MacDonald said that Queensland pharmacists are dedicated to ensuring the best outcomes for patients, and reiterated PSA’s support for the pilot and its extension.

 

“Pharmacists are following a strict protocol based on antimicrobial stewardship and best practice guidelines,” he said. “They cannot supply treatment unless the guidelines are closely followed.”

 

“Anything outside of the protocol is referred to another physician, which is in most cases a GP.

 

“The Queensland University of Technology’s final report on the pilot found that pharmacists have the appropriate skills, competencies, and training to manage the empiric treatment of uncomplicated UTIs in the community pharmacy.”

 

PSA strongly rejects comments made today by the Australian Medical Association (AMA).

 

“Pharmacists are registered health professionals with the same ethical and moral obligations as doctors.

 

“We have a health system that is approaching breaking point. The health profession needs to work together to support patients as their health needs become more complex. This includes reducing duplication and empowering patients with self-care.

 

“Measures like pharmacist vaccination and the treatment of uncomplicated UTI help free up precious doctor’s time for complex chronic disease management and more complex presentations.

 

“PSA has worked with Queensland Health to ensure appropriate clinical governance measures in the trial to support safe and effective patient care. The outcomes described in the evaluation report show these worked and serve as a model for broader rollout in the future.”

 

 

Media contact: Georgia Clarke 0487 922 176

 

 

Federal Health Minister to open PSA22

7 July 2022

 

The Pharmaceutical Society of Australia (PSA) is excited to confirm that Federal Minister for Health and Aged Care, the Hon. Mark Butler MP, will officially open PSA22 later this month.

 

PSA22 is Australia’s leading education conference for pharmacists and will be hosted by PSA from the 29th to 31st of July 2022 at the Hyatt Regency in Sydney.

 

PSA National President Dr Fei Sim thanked the Minister for giving Australia’s pharmacists the opportunity to learn more about the Albanese Government’s health priorities.

 

“Pharmacists played a significant role in the COVID-19 vaccine rollout, having delivered more than 7.5 million doses over the last twelve months.

 

“This will be a great opportunity to hear directly from the Minister about the incoming government’s agenda, and how we can continue to support the health and well-being of Australians.

 

“We are very excited to have the Minister joining us at PSA22, where hundreds of pharmacists from different backgrounds and clinical settings will come together to discuss the latest in pharmacy.

 

 

PSA22 will also feature a keynote address from former Australian Olympian turned Doctor, Jana Pittman, and MasterChef favourite, pharmacist Depinder Chhibber MPS will host this year’s Breakfast Mixer: 11 secret ingredients to the evolving role of pharmacists.

 

“Dr Pittman has a very inspiring story to tell of triumph, defeat, failure and success throughout her Olympic journey, and on her path to becoming a healthcare professional. She has demonstrated remarkable passion and resilience throughout her career. I know many PSA members were excited to follow Ms Chibber’s MasterChef journey, and to see a pharmacist in the public spotlight on national TV. I am thrilled to have both of these phenomenal women join us for PSA22.

 

“Of course, PSA22 is also an important platform for PSA’s policy and advocacy work. We will be launching PSA’s fifth medicine safety report, Medicine Safety: Disability Care, at this conference, as well as PSA’s Guidelines for pharmacists supporting Aboriginal and Torres Strait Islander people with medicine management.

 

“I would like to recognise our hardworking staff and members who have put their time and energy into these invaluable pieces of work, and I look forward to continuing profession-wide discussions on how pharmacists can better meet the needs of people living with disabilities, and Aboriginal and Torres Strait Islander people.

 

“This is an opportunity not to be missed. Get your tickets to PSA22 today and join us in Sydney later this month.”

Register for PSA22 here: www.psa22.com.au

 

 

Media contact: Georgia Clarke 0487 922 176

Health profession must work together and put patients first

7 July 2022

 

 

The Pharmaceutical Society of Australia (PSA) welcomes the Queensland Government’s announcement that the Urinary Tract Infection Pharmacy Pilot – Queensland (UTIPP-Q) will be extended.

 

PSA National President Dr Fei Sim says that pharmacists have proven their expertise and professionalism during the Queensland pilot.  

 

“PSA is proud to continue working with the Queensland Government to extend the pilot. This pilot allowed thousands of Queensland women to get timely access to treatments for uncomplicated UTIs from their local pharmacist.

 

“The Queensland University of Technology’s final report on the pilot found that pharmacists have the appropriate skills, competencies, and training to manage the empiric treatment of uncomplicated UTIs in the community pharmacy,” she said.

 

“PSA has worked with Queensland Health to ensure appropriate clinical governance measures in the trial to support safe and effective patient care. The outcomes described in the evaluation report show these worked and serve as a model for broader rollout in the future.

 

PSA strongly rejects comments made today by the Royal Australian College of General Practitioners (RACGP).

 

“Pharmacists are registered health professionals with the same ethical and moral obligations as doctors,” Dr Sim said.

 

“Community pharmacies are not ‘unsupervised retail settings’ – they are primary healthcare destinations, as well as the most accessible healthcare setting in Australia.

 

“Pharmacists undergo a minimum of five-years’ training, as well as additional education and training for this very trial, so that they can provide the best possible care to their patients.

 

“Measures like pharmacist vaccination and the UTI pilot help free up precious doctor’s time for complex chronic disease management and more complex presentations.

 

“We have a health system that is approaching breaking point. The health profession needs to work together to support patients as their health needs become more complex. This includes reducing duplication and empowering patients with self-care.

 

“Working together means putting aside turf wars and finding better ways to support patients. PSA will not apologise for our commitment to timely access to care. We remain committed to working collaboratively with the entire health sector to deliver best outcomes for patients.”

 

 

Media contact: Georgia Clarke 0487 922 176

Access to antivirals key to tackling next COVID-19 wave

5 July 2022

 

The Pharmaceutical Society of Australia (PSA) National President Dr Fei Sim is calling on governments to do more to protect the community and prepare for an increasing number of COVID-19 infections and hospitalisations by improving access to antiviral medicines.

 

Dr Sim says that governments – at both state/territory and federal levels – must take a pragmatic approach to ensure high-risk patients have timely access to antivirals, to avoid the shortages and last-minute policy-making that Australia saw with the rollouts of COVID-19 vaccines and Rapid Antigen Tests.

 

“We cannot sit and wait for infections and hospitalisations to rise further – governments must act now. Timely access to antivirals is critical to reduce the severity of COVID-19 infection and limiting complications.

 

“Governments must develop a process to triage high-risk patients, refer them to a prescriber, and ensure rapid supply. What is clear is that early access to antivirals leads to far better patient outcomes.

 

Dr Sim says that community pharmacists in Scotland have been able to supply antivirals like molnupiravir to high-risk COVID-19 patients since January 2022.

 

“Scotland’s utilisation of the pharmacist workforce to provide timely access to antivirals has had very positive impact on the health of patients who are at risk of hospitalisation or death due to COVID-19.

 

“It is incumbent upon the Federal Government to raise awareness with the general public of the importance of seeking antiviral treatment early.”

 

PSA is also calling on the Federal Government to restore funding for pharmacies to provide the COVID-19 Home Medicine Service in response to increasing infections.

 

“With rising petrol prices and supply costs, pharmacies cannot afford to continue providing these services for free. Restoring this funding would allow pharmacies to deliver antivirals to COVID-19 positive patients safely and quickly.

 

“I would like to remind all Australians to wear a mask when visiting their local pharmacy. It’s crucial that we continue to protect our frontline healthcare workers and vulnerable patients at this time.

 

“For many Australians, pharmacies are the first stop when they are feeling ill. It’s also where immunocompromised and high-risk patients need to go to collect their essential medicines. Please help protect your community by wearing a mask when you visit a pharmacy.”

 

Dr Sim has also called for frontline health workers, including pharmacists, to be eligible to receive a fourth dose of a COVID-19 vaccine.

 

“As some of the first to be vaccinated, health workers are more exposed than many to waning protection over time. Expanding the booster program to include pharmacists and other healthcare workers is the next necessary step.

 

“PSA is ready to work with the Federal government and all state and territory governments to ensure the safety of our communities, as well as our pharmacists.”

 

 

 

Media contact: Georgia Clarke 0487 922 176

 

PSA welcomes fast-tracked UTas Pharmacy program

1 July 2022

 

The Pharmaceutical Society of Australia (PSA) welcomes the University of Tasmania’s announcement of a three-year Bachelor of Pharmacy with Honours program set to begin in 2023.

 

The new program will deliver the same volume of learning as four-year programs and is the first of its kind in Australia. PSA Tasmania President David Peachey says the new program will accelerate more young pharmacists into the profession.

 

“Pharmacists have struggled with workforce capacity since the beginning of the pandemic, and as the role of pharmacists evolves, the profession needs to expand,” he said.

 

“This new program will give pharmacy students the opportunity to accelerate their learning and get into pharmacy sooner.

 

Mr Peachey said that while this program will be attractive to some students, greater focus needs to be put on attracting students to the profession.

 

“We need to encourage more students to take up pharmacy degrees by making a career as a pharmacist more attractive.

 

“PSA has been working with governments to improve conditions and remuneration for pharmacists that better reflects their standing in the healthcare system as well as their expertise, training, and skills.

 

“Being a pharmacist is a very rewarding career and PSA will continue advocating for a career that attracts the best and brightest young minds.

 

“PSA looks forward to working with the University of Tasmania and the School of Pharmacy and Pharmacology as their program begins.”

 

 

Media contact: Georgia Clarke 0487 922 176

The Pharmaceutical Society of Australia is the professional organisation of Australian pharmacists. PSA is the only government-recognised peak national body for pharmacists, representing all of the pharmacy profession in Australia.

 

WA free flu vaccination extension welcomed by pharmacists

30 June 2022

 

The Pharmaceutical Society of Australia (PSA) welcomes the extension of the free flu vaccination program in Western Australia until the end of July.

 

Incoming PSA WA State President Lusi Sheehan says the move will encourage more West Australians to get their flu shot.

 

“We know that cost is a significant barrier to many people getting a regular flu shot. Being able to deliver another month of vaccinations at no cost to the public makes a big difference,” she said.

 

“We need to make it easier for all Australians to be protected against influenza every year. We thank the WA State Government for supporting Pharmacy and removing cost barriers previously faced by many Western Australians.

 

“PSA has been calling for West Australians to have greater access to vaccinations by allowing pharmacist-immunisers to administer a wider range of vaccines.

 

“Community pharmacists have the clinical experience to deliver all vaccinations, including influenza vaccinations, and often have shorter waiting times than GPs.

 

“We must continue to make vaccinations more accessible for all Australians and ensure that governments support pharmacists to improve the ongoing health of their communities.

 

“I encourage every West Australian to get their no-cost flu shot at their local pharmacist as soon as they can.”

 

All WA residents aged 5 years and older can access an influenza vaccination at no-cost from their local community pharmacy until 31 July 2022.

 

 

 

Media contact: Georgia Clarke 0487 922 176